CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-27 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,250 | 242,620 | ||
| 2024-02-26 | Kintz Samuel PRESIDENT AND CEO | Option exercise 10b5-1 | +12,000 | $1.12 | $13K | 12,000 |
| 2024-02-26 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −7,624 | $16.69 | $127K | 4,376 |
| 2024-02-26 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −4,376 | $17.24 | $75K | 0 |
| 2024-02-26 | Kintz Samuel PRESIDENT AND CEO | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 272,550 | ||
| 2024-02-15 | Heyman Richard A. Director | Sale 10b5-1 | −1,270 | $17.42 | $22K | 144,740 |
| 2024-02-14 | 5AM Partners VI, LLC 10% owner | Sale | −688,358 | $14.90 | $10.3M | 3,200,634 |
| 2024-02-14 | 5AM Partners VI, LLC 10% owner | Sale | −136,642 | $14.90 | $2.0M | 635,341 |
| 2024-02-13 | Phillips Andrew John Director | Grant or award · Stock Option (right to buy) | +23,364 | 23,364 | ||
| 2024-02-13 | Heyman Richard A. Director | Grant or award · Stock Option (right to buy) | +29,205 | 29,205 | ||
| 2024-02-13 | Gupta Rishi Director | Grant or award · Stock Option (right to buy) | +23,364 | 23,364 | ||
| 2024-02-13 | Derynck Mika K Director | Grant or award · Stock Option (right to buy) | +23,364 | 23,364 | ||
| 2024-02-13 | Bauer Jake Director | Grant or award · Stock Option (right to buy) | +23,364 | 23,364 | ||
| 2024-02-13 | Ballal Rahul D. Director | Grant or award · Stock Option (right to buy) | +23,364 | 23,364 | ||
| 2024-02-13 | Phillips Andrew John Director | Grant or award · Stock Option (right to buy) | +16,835 | 16,835 | ||
| 2024-02-13 | Patel Anish CHIEF OPERATING OFFICER | Grant or award · Stock Option (right to buy) | +185,000 | 185,000 | ||
| 2024-02-13 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Grant or award · Stock Option (right to buy) | +185,000 | 185,000 | ||
| 2024-02-13 | Kintz Samuel PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +410,000 | 410,000 | ||
| 2024-02-13 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +185,000 | 185,000 | ||
| 2024-02-13 | Heyman Richard A. Director | Grant or award · Stock Option (right to buy) | +21,043 | 21,043 |
Page 25 of 37 · 724 trades